Search
                    Cisplatin Treatment Options in Texas
A collection of 537 research studies where Cisplatin is the interventional treatment. These studies are located in the Texas, United States. Cisplatin is used for conditions such as Head and Neck Cancer, Lung Cancer and Non-Small Cell Lung Cancer.
            529 - 537 of 537
        Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
                                
            
            
        Unknown
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase I trial to study the effect of combination chemotherapy on the body when treating patients who have relapsed or refractory aggressive non-Hodgkin's lymphoma.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 64 years
            Trial Updated:
                07/04/2009
            
            Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas         
        
        
            Conditions: Lymphoma
        
            
        
    
                
                                    Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
                                
            
            
        Unknown
                            
            
                RATIONALE: Drugs used in chemotherapy, such as pixantrone, cytarabine, methylprednisolone, and cisplatin, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have relapsed aggressive non-Hodgkin's lymphoma.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/04/2009
            
            Locations: Baylor University Medical Center, Dallas, Texas  +1 locations         
        
        
            Conditions: Lymphoma
        
            
        
    
                
                                    IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
                                
            
            
        Completed
                            
            
                The primary purpose of this study is to assess the effectiveness of ZD1839 250 mg and 500 mg when given either concomitantly or as maintenance to a standard therapy of radiotherapy (X-rays) plus chemotherapy (cisplatin) in terms of local disease control (progression-free) rate at 2 years.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/17/2009
            
            Locations: Research Site, Dallas, Texas         
        
        
            Conditions: Neoplasms, Squamous Cell
        
            
        
    
                
                                    Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
                                
            
            
        Completed
                            
            
                This study aims to determine how successful the chemotherapy regimen of Pemetrexed plus cisplatin before surgery is at killing all the tumor so that none is left at the time of surgery. Following surgery, all eligible patients will receive radiation to the chest. How patients respond, whether the cancer returns and if so, where, will also be monitored.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/01/2009
            
            Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas         
        
        
            Conditions: Pleural Neoplasms
        
            
        
    
                
                                    Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer
                                
            
            
        Unknown
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. Combining hyperthermia with chemotherapy and interferon alfa may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects of cisplatin, gemcitabine, interferon alfa, and whole-body hyperthermi...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/29/2009
            
            Locations: University of Texas Health Science Center at Houston, Houston, Texas         
        
        
            Conditions: Unspecified Adult Solid Tumor, Protocol Specific
        
            
        
    
                
                                    Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors
                                
            
            
        Completed
                            
            
                This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                01/16/2009
            
            Locations: Institute for Drug DevelopmentCancer Therapy & Research Center, San Antonio, Texas         
        
        
            Conditions: Advanced Solid Tumors
        
            
        
    
                
                                    A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer
                                
            
            
        Completed
                            
            
                The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine and cisplatin in patients with non-small cell lung cancer.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                12/17/2007
            
            Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Houston, Texas         
        
        
            Conditions: Carcinoma, Non-Small-Cell Lung
        
            
        
    
                
                                    Study of Talabostat and Cisplatin in Advanced Melanoma
                                
            
            
        Completed
                            
            
                The purpose of this study is to assess the antitumor activity and safety of the combination of talabostat and cisplatin in patients with metastatic melanoma.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/07/2007
            
            Locations: Mary Crowley Medical Research Center, Dallas, Texas  +1 locations         
        
        
            Conditions: Melanoma, Skin Cancer
        
            
        
    
                
                                    Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer
                                
            
            
        Completed
                            
            
                The purposes of this study are: To determine the maximum tolerated dose of Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine in patients with advanced or metastatic transitional cell carcinoma of the urothelium; To determine the safety of Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine and any side effects that might be associated with the combination of these drugs; To determine whether Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine can help patien...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/24/2006
            
            Locations: For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Dallas, Texas         
        
        
            Conditions: Carcinoma, Transitional Cell
        
            
        
    529 - 537 of 537
            